Ovarian Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Ovarian Cancer, including details on symptoms, causes, treatment, information.

Volume 4 (2007), Issue 10 (October)

1. Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study.
   J Clin Oncol, 25(28): 4466-71. [Abstract] [Full-text]
2. Sheep stromal-epithelial cell interactions and ovarian tumor progression.
   Int J Cancer, 121(10): 2346-54. [Abstract] [Full-text]
3. A prospective study of dietary flavonoid intake and incidence of epithelial ovarian cancer.
   Int J Cancer, 121(10): 2225-32. [Abstract] [Full-text]
4. Antitumor and antivascular effects of AVE8062 in ovarian carcinoma.
   Cancer Res, 67(19): 9337-45. [Abstract] [Full-text]
5. Insulin receptor substrate-1 is an important mediator of ovarian cancer cell growth suppression by all-trans retinoic acid.
   Cancer Res, 67(19): 9266-75. [Abstract] [Full-text]
6. In vivo imaging of the systemic recruitment of fibroblasts to the angiogenic rim of ovarian carcinoma tumors.
   Cancer Res, 67(19): 9180-9. [Abstract] [Full-text]
7. Epithelial-mesenchymal interconversions in normal ovarian surface epithelium and ovarian carcinomas: an exception to the norm.
   J Cell Physiol, 213(3): 581-8. [Abstract] [Full-text]
8. Binding of endostatin to human ovarian cancer cells inhibits cell attachment.
   Int J Cancer, 121(11): 2402-9. [Abstract] [Full-text]
9. Enhanced repair of DNA interstrand crosslinking in ovarian cancer cells from patients following treatment with platinum-based chemotherapy.
   Br J Cancer, 97(7): 927-33. [Abstract] [Full-text]
10. MR imaging in ovarian cancer.
    Cancer Imaging, 7: S119-29. [Abstract] [Full-text]
11. Stage I ovarian carcinoma: different clinical pathologic patterns.
    Fertil Steril, 88(4): 906-10. [Abstract] [Full-text]
12. Stromal-cell derived factor-1 regulates epithelial ovarian cancer cell invasion by activating matrix metalloproteinase-9 and matrix metalloproteinase-2.
    Eur J Cancer Prev, 16(5): 430-5. [Abstract] [Full-text]
13. Use of cosmetic talc on contraceptive diaphragms and risk of ovarian cancer: a meta-analysis of nine observational studies.
    Eur J Cancer Prev, 16(5): 422-9. [Abstract] [Full-text]
14. Genetic changes in the evolution of multidrug resistance for cultured human ovarian cancer cells.
    Genes Chromosomes Cancer, 46(12): 1069-79. [Abstract] [Full-text]
15. BRCA1 and BRCA2 genetic testing in Hispanic patients: mutation prevalence and evaluation of the BRCAPRO risk assessment model.
    J Clin Oncol, 25(29): 4635-41. [Abstract] [Full-text]
16. Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer.
    J Clin Oncol, 25(29): 4528-35. [Abstract] [Full-text]
17. Peritoneal natural killer cells from epithelial ovarian cancer patients show an altered phenotype and bind to the tumour marker MUC16 (CA125).
    Immunology, 122(3): 418-29. [Abstract] [Full-text]
18. Vascular endothelial growth factor staining and elevated INR in advanced epithelial ovarian carcinoma.
    J Surg Oncol, 96(6): 514-7. [Abstract] [Full-text]
19. Low-fat dietary pattern and cancer incidence in the Women's Health Initiative Dietary Modification Randomized Controlled Trial.
    J Natl Cancer Inst, 99(20): 1534-43. [Abstract] [Full-text]
20. Synergistic effects of epidermal growth factor and hepatocyte growth factor on human ovarian cancer cell invasion and migration: role of extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase.
    Endocrinology, 148(11): 5195-208. [Abstract] [Full-text]
21. Laparoscopic restaging of borderline ovarian tumors.
    Surg Endosc, 21(11): 2039-43. [Abstract] [Full-text]
22. Bevacizumab in the treatment of ovarian cancer.
    Expert Rev Anticancer Ther, 7(10): 1339-45. [Abstract] [Full-text]
23. Familial breast/ovarian cancer and BRCA1/2 genetic screening: the role of immunohistochemistry as an additional method in the selection of patients.
    J Histochem Cytochem, 55(11): 1105-13. [Abstract] [Full-text]
24. Clinical trial endpoints in ovarian cancer: report of an FDA/ASCO/AACR Public Workshop.
    Gynecol Oncol, 107(2): 173-6. [Abstract] [Full-text]
25. Treatment of pulmonary recurrences in patients with endometrial cancer.
    Gynecol Oncol, 107(2): 242-7. [Abstract] [Full-text]
26. Influence of platinum-based chemotherapy on disseminated tumor cells in blood and bone marrow of patients with ovarian cancer.
    Gynecol Oncol, 107(2): 331-8. [Abstract] [Full-text]
27. Novel cytotoxic agents from an unexpected source: bile acids and ovarian tumor apoptosis.
    Gynecol Oncol, 107(2): 344-9. [Abstract] [Full-text]
28. S1P and LPA have an attachment-dependent regulatory effect on invasion of epithelial ovarian cancer cells.
    Gynecol Oncol, 107(2): 298-309. [Abstract] [Full-text]
29. Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer.
    Gynecol Oncol, 107(2): 326-30. [Abstract] [Full-text]
30. Expression analysis and RNA localization of PAI-RBP1 (SERBP1) in epithelial ovarian cancer: association with tumor progression.
    Gynecol Oncol, 107(2): 266-73. [Abstract] [Full-text]
31. Weight change during chemotherapy as a potential prognostic factor for stage III epithelial ovarian carcinoma: a Gynecologic Oncology Group study.
    Gynecol Oncol, 107(2): 260-5. [Abstract] [Full-text]
32. Risk factors for benign, borderline and invasive mucinous ovarian tumors: epidemiological evidence of a neoplastic continuum?
    Gynecol Oncol, 107(2): 223-30. [Abstract] [Full-text]
33. Accuracy of intraoperative frozen section analysis in borderline tumors of the ovary: a retrospective analysis of 96 cases and review of the literature.
    Gynecol Oncol, 107(2): 248-52. [Abstract] [Full-text]
34. Computed tomography features of recurrent ovarian carcinoma according to time to relapse.
    Acta Radiol, 48(9): 1038-44. [Abstract] [Full-text]
35. 8-benzyl-4-oxo-8-azabicyclo[3.2.1]oct-2-ene-6,7-dicarboxylic acid (SD-1008), a novel janus kinase 2 inhibitor, increases chemotherapy sensitivity in human ovarian cancer cells.
    Mol Pharmacol, 72(5): 1137-45. [Abstract] [Full-text]
36. Intraperitoneal photodynamic therapy for an ovarian cancer ascite model in Fischer 344 rat using hematoporphyrin monomethyl ether.
    Cancer Sci, 98(12): 1959-64. [Abstract] [Full-text]
37. Simultaneous inhibition of the mitogen-activated protein kinase kinase and phosphatidylinositol 3'-kinase pathways enhances sensitivity to paclitaxel in ovarian carcinoma.
    Cancer Sci, 98(12): 2002-8. [Abstract] [Full-text]
38. Hypoxia enhances LPA-induced HIF-1alpha and VEGF expression: their inhibition by resveratrol.
    Cancer Lett, 258(1): 63-9. [Abstract] [Full-text]
39. Prospective study of the correlation between postoperative computed tomography scan and primary surgeon assessment in patients with advanced ovarian, tubal, and peritoneal carcinoma reported to have undergone primary surgical cytoreduction to residual disease 1 cm or less.
    J Clin Oncol, 25(31): 4946-51. [Abstract] [Full-text]

© 2004-2008 Ovarian Cancer Research Today. All Rights Reserved.